Update from the Office of Generic Drugs Gary J. Buehler, R.Ph. Director, Office of Generic Drugs Center for Drug Evaluation and Research Food & Drug Administration.

Slides:

Advertisements

Similar presentations

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

Advertisements

ICH Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC) Overview and Update Robert H. King, Sr. Office of Pharmaceutical.

U.S. Food and Drug Administration

BOT Retreat: Strategic Priorities for 2007 ACC Board of Trustees August 2006.

2 nd National Staff Meeting April 19 – 21, 2006 Tagaytay City Updates on FOURmula 1 for Health (NSM Resolution No ) Mario C. Villaverde, MD,MPH,MPM,CESO.

Implementation Council Meeting Structure and Resources Background: The Implementation Council (Council) roles and responsibilities are described in the.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Regulatory.

Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.

Regulation of Generic Drugs Office of Generic Drugs Craig Kiester Regulatory Support Branch.

Individual Bioequivalence Lawrence J. Lesko, Ph.D. Director Office of Clinical Pharmacology and Biopharmaceutics Advisory Committee for Pharmaceutical.

1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.

Requirements for Standardized Study Data: Update on Guidance Ron Fitzmartin, PhD, MBA Data Standards Program Office of Strategic Programs Center for Drug.

21 CFR Part 11 A Food Industry Perspective FDA Public Meeting June 11, 2004 Sia Economides Center Director Center for Development of Research Policy and.

Overview of the New Content and Format Requirements for Prescription Drug Labeling.

What You Want to Know About Generic Drugs Generic Drugs: Safe. Effective. FDA-Approved.

Organizational Gaps in Reaching the “Desired State” Helen Winkle.

Justina A. Molzon, MS Pharm, JD

Overview of FDA's Regulatory Framework for PET Drugs

Scientific Data for Evidence- Based Drug Regulation Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research Food and Drug Administration.

Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.

eCTD: Module 1 from submission to reviewer

Institute of Food Technologists (IFT) myIFT.org Overview Paul D. Grassman Director, Information Services September 2003.

1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.

DIABETES AND SCIENCE EDUCATION IN AMERICAN INDIAN SCHOOLS: Time Line Lawrence Agodoa, M.D. Director, Office of Minority Health Research Coordination National.

Communication of Drug Safety Information Food and Drug Administration Center for Drug Evaluation & Research Public Hearing December 8, 2005.

Lina Williams Budget & Financial Analyst Christopher M. Quinn, MACC, CPA, CFE, CGFO, CGMA Finance Director Tuesday, April 28 th, 2015.

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

Quality by Design & Question-Based Review: Observations by the Generic Pharmaceutical Industry Advisory Committee for Pharmaceutical Science October 5,

1 Advisory Committee for Pharmaceutical Science October 26, 2005 Advisory Committee for Pharmaceutical Science October 26, 2005 Implementation of Quality-by-Design.

Overview of FDA's Regulatory Framework for PET Drugs

Risk-Based CMC Review - OGD Perspective Gary J. Buehler, R.Ph. Director Office of Generic Drugs July 21, 2004 Advisory Committee for Pharmaceutical Science.

COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.

OPDP Update on Oversight of Prescription Drug Promotion Thomas Abrams Director Office of Prescription Drug Promotion Food and Drug Administration September.

Government Impact on Adoption and Expansion of eSignatures and eRecords Kevin Hatton Director, E-file Provider Program Management Internal Revenue Service.

FDA Office of Orphan Products Development

Homeland Security Funding Urban Areas Security Initiative November 1, 2006.

Catalysts for enactment of PDUFA  Amendments to FD&C Act  Origin of modern drug development process  Requirement that drugs be shown to be safe.

Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.

1 Office of Pharmaceutical Science on Jon Clark FDA/CDER/OPS Associate Director for Policy Development.

Labeling and Electronic Initiatives Rachel E. Behrman M.D., M.P.H. Deputy Director, Office of Medical Policy CDER FDA Science Board, April 15, 2005.

Master Plan Process FY Proposed Draft. October - February Cluster Groups and Units Identify Initiatives These are general goals or outcomes that.

Office of Drug Safety Updates Drug Safety and Risk Management Advisory Committee Meeting February 10, 2006 Gerald J. Dal Pan, MD, MHS Director, Office.

FDA Standards Development and Implementation Randy Levin, M.D. Director, Office of Information Management Center for Drug Evaluation and Research Food.

CDISC – 17/12/2012 Carine Javierre Nathalie SABIN.

October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

Bioequivalence Criteria Research Plan Stella G. Machado, Ph.D. Office of Biostatistics and the Replicate Design Technical Committee Advisory Committee.

Lawrence X. Yu, Ph.D. Director for Science Office of Generic Drugs, OPS, CDER, FDA ACPS Meeting, ACPS Meeting, Oct. 22, 2003 Office of Generic Drugs Research.

Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.

Use of Risk-based Approach for Regulating CMC Changes to Approved Applications FDA Public Meeting February 7, 2007.

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.

CDER/Office of Generic Drugs1 Regulatory Issues Related to Crystal Habits - Polymorphism 1:45 - 2:00Polymorphs - What’s the Problem? Gary Buehler, R. Ph.,

ANDA REGULATORY APPROVAL PROCESS. Abbreviated new drug application (ANDA) These are submitted to the FDA’s CDER(center for drug evaluation and research)

© Copyright IBM 2007DIA ERS SIAC Presentation, January 2008 The HL7 RPS and SPL Standards - A High Level View Terry Hardin Sr. IT Architect Emerging Software.

Office of Pharmaceutical Science OPS Center for Drug Evaluation and Research CDER FDA Food and Drug Administration HHS Health and Human Services 1 Advisory.

Regulated Product Submission Eileen M. Girten, MS i3 Statprobe 1DIA Education SIAC.

Recent Activities for LIEE and CARE November 2007 Proposed decision submission (R ) Proposed decision submission (R ) IOU reporting.

David J. Hauss, PhD, RPh Regeneron Pharmaceuticals, Inc. Tarrytown, NY.

Collaborative Pilot Project: Connecting EMRs with the IL PMP to Improve Medication Safety IL Prescription Monitoring Program IHA’s Institute for Innovations.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on the Somatic Cell.

Teacher Evaluation Timeline

Performance Management Strategic Initiative January 2017 Update

CTD Content Management

FDA Experience with eCTD

Cost of Service Analysis & Rate Design

Presented to the Project Certification Committee on June

Budget and Planning Update

Review plan of the nature reporting – update 6

TEXAS DSHS HIV Care services group

Presentation transcript:

Update from the Office of Generic Drugs Gary J. Buehler, R.Ph. Director, Office of Generic Drugs Center for Drug Evaluation and Research Food & Drug Administration March 2, 2004 Generic Pharmaceutical Association 2004 Annual Meeting

Center for Drug Evaluation & Research2 Office of Generic Drugs Full and Tentative Approvals of ANDAs (306)(310)(294)(249)(266)(364)(373)

Center for Drug Evaluation & Research3 Office of Generic Drugs

Center for Drug Evaluation & Research4 Office of Generic Drugs Receipts of Original ANDA Applications

Center for Drug Evaluation & Research5 Office of Generic Drugs

Center for Drug Evaluation & Research6 Office of Generic Drugs

Center for Drug Evaluation & Research7 Workload Backlog and Staffing Chemistry FY01FY02FY03FY04 Backlog days days±100 days Staffing 60 (at end of FY) Lost 4 Gained 8 Lost 2 Gained 12 Lost 2 Gained 2 Pending * Receipts * * as of 1/31/2004

Center for Drug Evaluation & Research8 New Chemistry Review Division Chemistry Division 1 Team 1 Team 4 Team 5 Team 2 Chemistry Division 2 Team 6 Team 9 Team 10 Team 7 Team 3Team 8 Chemistry Division 3 Team 4 Team 6Team +

Center for Drug Evaluation & Research9 Workload Backlog and Staffing Microbiology FY01FY02FY03FY04 Backlog (Orig) 210 days343 days280 days86 days* Staffing 4 (at end of FY) Lost TL Gained TL +1 Lost 0 Gained 1 Lost 0 Gained 1 Backlog (Supp) 209 days110 days113 days90 days* Pending * Receipts * * as of 1/31/2004

Center for Drug Evaluation & Research10 Workload Backlog and Staffing Bioequivalence FY01FY02FY03FY04 Backlog±49 days118 days200+ days226 days* Staffing 30 (at end of FY) Lost 4 Gained 0 Lost 2 Gained 5 Lost 0 Gained 2 Pending * Receipts * * as of 1/31/2004

Center for Drug Evaluation & Research11 Scientific Staff n FY2002 v Lawrence Yu n FY2003 FY projected v Robert Lionberger  Andre Raw v Sam Haider v Hyojong Kwon v Pradeep Sathe v Qian Li

Center for Drug Evaluation & Research12 Clinical Review Staff n FY2002 v Dena Hixon, MD n FY2003 FY projected v Carol Kim  Additional MD v Krista Scardina v Helen Li (Statistician) v Sarah Ho

Center for Drug Evaluation & Research13 Other Activities n Listed Drug Guidance v Directed by new law v Drafted; under review n OGD/Office of Chief Counsel (OCC) determining regulation revisions or changes necessitated by new law n OGD/GPhA Communications

Center for Drug Evaluation & Research14 Interaction to Facilitate Efficient Approval of Applications n June 11, Impurities - Lawrence Yu n June 26, General discussion - Need for dissolution database identified n September 24, Webcast on Impurities n October 15, 16, 17, Fall Technical Conference n November 5 & 6, First “ANDA Basics” Workshop n February 4 & 5, Second “ANDA Basics” Workshop n February 10, Webcast on cGMP n TO COME: v April 20, 2004 – Preparing CTD/eCTD Workshop

Center for Drug Evaluation & Research15 Budget Outlook n FY2004 v Not yet finalized n FY2005 v Proposed the same as FY2004 v Can’t predict what will happen

Center for Drug Evaluation & Research16 Bioequivalence Information Availability n Dissolution Methods database v Will be available March 2004 v Will be initially populated with older products v Newly approved products will be added incrementally n In-Vivo Bioequivalence Recommendations database being planned

Center for Drug Evaluation & Research17 DRAFT ben

Center for Drug Evaluation & Research18

Center for Drug Evaluation & Research19 Orange Book Revisions n Increased staffing to improve service Will go to daily patent listings ≈ April 2004 n New search capability for patent listings from OB webpage

Center for Drug Evaluation & Research20

Center for Drug Evaluation & Research21

Center for Drug Evaluation & Research22 CDER Electronic Submission Initiatives n Electronic-Common Technical Document v Pilot program has begun v G for I: Providing Regulatory Submissions in Electronic Format—Human Pharmaceutical Product Applications and Related Submissions n ANDAs, DMFs, NDAs, BLAs, INDs v Efficient, flexible approach v Uses e-CTD Viewer System (EVS) v Commercial tools available for creating e-CTD

Center for Drug Evaluation & Research23 CDER Electronic Submission Initiatives n E-Labeling Submissions v Implementation of a Structured Drug Label v A repository to house all labels v Develop tools to review and keep labels current v FR, February 5, 2004, Docket No. 2004D-0041 v G for I: Providing Regulatory Submissions in Electronic Format – Content of Labeling

Center for Drug Evaluation & Research24 E-Submissions/E-CTD Additional information and specifications CDER/Office of Information Management ERSR Technical Support:

Center for Drug Evaluation & Research25 For the Future: n Continue to maximize our review efficiency n Continue to focus resources on backlogged review areas n Continue to interact regularly with GPhA to discuss critical issues n Expand the Dissolution Methods database n Create a In-Vivo Bioequivalence Recommendations database

Center for Drug Evaluation & Research26

Center for Drug Evaluation & Research27 February 11, 2004 n OGD approved 13 applications for Benazepril or Benazepril/HCTZ n 2002 Sales for Lotensin ® (the RLD) were $315 million (ranks 97 th ) n In one week, the retail price of a month’s supply of Benazepril fell from $44 to $26 (40% decrease) n Approximate annual savings of 100 million dollars

Center for Drug Evaluation & Research28 Final Words... n The generic drug industry has done more to address the spiraling health costs in this country than any other industry n More than 50% of all prescriptions dispensed are supplied by your industry and reviewed by my office WW e are making a difference...

Center for Drug Evaluation & Research29 Office of Generic Drugs